v3.26.3
Segment and Geographic Data
9 Months Ended
Sep. 30, 2026
Segment Reporting [Abstract]  
Segment Information SEGMENT INFORMATION
We segregate our operations into two reportable business
segments: (i) MedSurg and Neurotechnology and (ii)
Orthopaedics which aligns to our internal reporting structure and
how our Chief Operating Decision Maker (CODM) assesses the
performance and allocates resources. The CODM is the Chief
Executive Officer. The CODM makes decisions on resource
allocation, assesses performance of the business, and monitors
budget versus actual results using segment operating income.
Information about total assets by segment is not disclosed
because such information is not regularly provided to, or used by,
our CODM.
Segment Results
Three Months
Nine Months
2026
2025
2026
2025
MedSurg and Neurotechnology
$3,664
$3,355
$10,496
$9,716
Orthopaedics
2,856
2,702
8,633
8,229
Net sales
$6,520
$6,057
$19,129
$17,945
MedSurg and Neurotechnology
$1,367
$1,294
$4,001
$3,732
Orthopaedics
818
769
2,479
2,325
Cost of sales
$2,185
$2,063
$6,480
$6,057
MedSurg and Neurotechnology
$242
$229
$728
$666
Orthopaedics
161
158
470
476
Segment research, development and
engineering expenses
$403
$387
$1,198
$1,142
MedSurg and Neurotechnology
$944
$902
$2,817
$2,670
Orthopaedics
855
776
2,550
2,445
Segment selling, general and
administrative expenses
$1,799
$1,678
$5,367
$5,115
MedSurg and Neurotechnology
$59
$56
$179
$170
Orthopaedics
131
123
389
353
Segment depreciation and
amortization
$190
$179
$568
$523
Corporate and Other
$32
$34
$98
$87
Amortization of intangible assets
175
189
530
543
Total depreciation and amortization
$397
$402
$1,196
$1,153
MedSurg and Neurotechnology
$1,052
$874
$2,771
$2,478
Orthopaedics
891
876
2,745
2,630
Segment operating income
$1,943
$1,750
$5,516
$5,108
Items not allocated to segments:
Corporate and Other
$(237)
$(200)
$(732)
$(669)
Inventory stepped up to fair value
—
(61)
—
(160)
Acquisition and integration-related
charges
(17)
(39)
(61)
(302)
Amortization of intangible assets
(175)
(189)
(530)
(543)
Structural optimization and other special
charges
(153)
(41)
(366)
(93)
Goodwill and other impairments
(293)
(73)
(294)
(163)
Medical device regulation
(6)
(11)
(16)
(30)
Recall-related matters
4
(1)
(8)
(56)
Regulatory and legal matters
(32)
—
(38)
(7)
Reversal of 2025 tariffs
—
—
158
—
Consolidated operating income
$1,034
$1,135
$3,629
$3,085